Exploring the Selinexor STOMP Trial
Join Dr. Chakraborty to learn about the Selinexor STOMP Trial and get answers to your questions like:
- Why test selinexor with so many different myeloma treatments aka why so many arms?
- What are we looking to discover and how soon could we get results?
- How can patients enroll in the trial, who qualifies for the clinical trials, and why should they join?
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Dr. Rajshekhar Chakraborty
Rajshekhar Chakraborty, MD is an assistant professor of medicine at Columbia University Irving Medical Center in the division of hematology/oncology. After receiving his medical degree from University of Delhi, India, he completed his residency in internal medicine at Icahn School of Medicine at Mount Sinai-Queens Hospital Center. Subsequently, he spent three years as a clinical researcher in plasma cell disorders at the Mayo Clinic, Rochester, followed by fellowship in hematology/oncology at the Cleveland Clinic. Dr. Chakraborty cares primarily for patients with plasma cells disorders, including multiple myeloma, amyloidosis, MGUS, POEMS syndrome, and Waldenstrom's macroglobulinemia. His research interests include clinical trials and outcomes research in plasma cell disorders.